{"id":61373,"date":"2026-03-26T14:40:28","date_gmt":"2026-03-26T06:40:28","guid":{"rendered":"https:\/\/flcube.com\/?p=61373"},"modified":"2026-03-26T14:40:28","modified_gmt":"2026-03-26T06:40:28","slug":"sinomab-bioscience-reports-positive-phase-i-bridging-data-for-sm17-first-in-class-il-25-receptor-antibody-advances-route-conversion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61373","title":{"rendered":"SinoMab BioScience Reports Positive Phase I Bridging Data for SM17 \u2013 First-in-Class IL-25 Receptor Antibody Advances Route Conversion"},"content":{"rendered":"\n

SinoMab BioScience Ltd<\/strong> (HKG: 3681<\/a>) announced positive readouts<\/strong> from a Phase I bridging study in China<\/strong> evaluating route of administration conversion<\/strong> for SM17<\/strong>, a novel first-in-class humanized IgG4-\u03ba monoclonal antibody<\/strong> targeting the interleukin-25 (IL-25) receptor (IL-17RB)<\/strong>. The study supports formulation optimization<\/strong> for this type 2 inflammatory modulator<\/strong>, which inhibits ILC2 and Th2 cell signaling<\/strong> and downregulates IL-4, IL-5, and IL-13<\/strong> production.<\/p>\n\n\n\n

Clinical Study Overview<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Study Phase<\/strong><\/td>Phase I (bridging study)<\/td><\/tr>
Objective<\/strong><\/td>Route of administration conversion evaluation<\/td><\/tr>
Geography<\/strong><\/td>China<\/td><\/tr>
Product<\/strong><\/td>SM17 (humanized IgG4-\u03ba monoclonal antibody)<\/td><\/tr>
Target<\/strong><\/td>IL-25 receptor (IL-17RB)<\/strong> \u2013 type 2 immune alarmin pathway<\/td><\/tr>
Result<\/strong><\/td>Positive readouts<\/strong> supporting formulation\/route optimization<\/td><\/tr>
Announcement Date<\/strong><\/td>26\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

SM17 Mechanism of Action<\/h2>\n\n\n\n
Biological Target<\/th>Cellular Expression<\/th>Therapeutic Effect<\/th><\/tr><\/thead>
IL-25 Receptor (IL-17RB)<\/strong><\/td>Type 2 innate lymphoid cells (ILC2s), Th2 cells<\/td>Blocks IL-25-mediated type 2 inflammation signaling<\/td><\/tr>
Downstream Cytokines<\/strong><\/td>IL-4, IL-5, IL-13<\/td>Downregulation<\/strong> of key type 2 inflammatory mediators<\/td><\/tr>
Clinical Application<\/strong><\/td>Atopic dermatitis, asthma, allergic rhinitis, eosinophilic esophagitis<\/td>First-in-class IL-25 pathway inhibition<\/strong> vs. IL-4\/IL-13 (dupilumab) or IL-5 (mepolizumab)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Competitive Position<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
Type 2 Inflammation Market<\/strong><\/td>$20+ billion globally<\/strong> (atopic dermatitis, asthma, biologics); IL-25 represents upstream “alarmin” target<\/strong> with potential for broader efficacy<\/td><\/tr>
First-in-Class Position<\/strong><\/td>Only IL-25 receptor antibody<\/strong> in clinical development; addresses ILC2-driven inflammation<\/strong> not targeted by current biologics<\/td><\/tr>
Route Conversion Rationale<\/strong><\/td>Bridging study supports subcutaneous or alternative formulation<\/strong> vs. IV \u2013 improves patient convenience and commercial scalability<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Dupilumab (IL-4R, $10B+), tralokinumab (IL-13), tezepelumab (TSLP); SM17’s IL-25 upstream positioning<\/strong> may offer combination or superior monotherapy potential<\/strong><\/td><\/tr>
China Development Strategy<\/strong><\/td>Bridging study enables NMPA Phase II\/III initiation<\/strong>; potential for China-first approval<\/strong> given unmet need in severe atopic dermatitis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n